ArticleBMC nutrition2025
Effect of zinc supplementation on atherogenic risk indices in patients with non-alcoholic fatty liver disease: a randomized, double-blinded, placebo-controlled clinical trial.
Article in BMC nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundZinc (Zn) deficiency is common in non-alcoholic fatty liver disease (NAFLD) patients, and this trace element plays an essential role in lipid profile control. The atherogenic index of plasma (AIP), atherogenic coefficient (AC), Castelli risk index I, and Castelli risk index II predict atherogenic statuses. This study aimed to evaluate the effect of Zn supplementation on atherogenic indices in NAFLD patients.
methodsIn this 8-week randomized, double-blinded, placebo-controlled clinical trial 50 overweighed or obese individuals suffering from NAFLD were randomly allocated into 2 groups of 25. In addition to a balanced energy-restricted diet and physical activity recommendations, participants were assigned to receive either 30 mg/d Zn or a placebo in the intervention or control group, respectively.
resultsThe mean differences for energy (P = 0.761), protein (P = 0.373), fiber (P = 0.799), and zinc (P = 0.653) intakes were not statistically significant. In contrast, the mean differences for daily carbohydrate consumption (P = 0.011) and fat intake (P < 0.001) were significantly different between groups. After the study, the between-group comparisons revealed that the reduction in Castelli risk index II (P = 0.034) was significant; however, no significant differences were found for AIP (P = 0.103), AC (P = 0.113), or Castelli risk index I (P = 0.113).
conclusionBased on the results, supplementation with 30 mg/d Zn for 8 weeks may significantly reduce the Castelli Risk Index II, a potential marker of cardiovascular risk, and decrease CVD risk, but further studies with larger sample sizes or longer intervention durations are suggested.
trial registrationThe trial was retrospectively registered at IRCT.ir as IRCT20191015045113N1 (December/8/2019).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.